Acupoint plaster added to standard anti-nausea medicine for lung cancer patients on platinum chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, randomized study in adults with lung cancer to see if an acupoint plaster applied to specific points, in addition to standard anti-nausea medication, improves control of delayed nausea and vomiting during the first cycle of platinum-based chemotherapy. Participants are randomly assigned to receive the acupoint treatment plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone, with nausea/vomiting captured in patient diaries and quality of life measured by the FLIE questionnaire. The trial includes adults 18–75, with adequate performance status, and excludes those with skin issues at treatment sites or prior interventional trial participation within 30 days. Primary outcome focuses on complete control of delayed nausea and vomiting across the chemotherapy cycle.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pathologically or cytologically confirmed lung cancer.
* Scheduled to receive first-line platinum-based chemotherapy.
* Aged 18 to 75 years.
* Karnofsky Performance Status (KPS) score ≥ 60.
* Expected survival ≥ 3 months.
* Voluntarily signed written informed consent.

Exclusion Criteria:

* Known allergy to any component of the acupoint plaster.
* Severe skin disease, infection, or breakdown at the planned acupoint sites. --Pregnant or lactating women.
* Cognitive impairment or psychiatric disorder that prevents completion of study assessments.
* Participation in another interventional clinical trial within 30 days prior to enrollment.

Where it's running

• The Affiliated Yongchuan Hospital of Chongqing Medical University
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Study coordinator: Xiu Huang
• Email: 104100275@qq.com
• Phone: +8615023119040

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fosaprepitant plus palonosetron with dexamethasone (± olanzapine) to prevent nausea from multi-day highly emetogenic chemotherapy

  This trial tests whether giving fosaprepitant and palonosetron with dexamethasone, with or without olanzapine, can prevent nausea and vomiting in adults starting multi-day highly emetogenic chemotherapy.

  Recruiting Phase 4 Shanghai 6th People's Hospital · Shanghai, Shanghai Municipality · NCT07482891

• Comparing olanzapine to placebo for preventing nausea from chemotherapy

  This study tests if the medication olanzapine can help prevent nausea and vomiting in people getting chemotherapy for the first time.

  Recruiting Phase 3 Mahidol University · Bangkok, Bangkok · NCT06850454

• Using Dolasetron to Prevent Nausea and Vomiting in Children with Leukemia

  This study is testing if dolasetron can help prevent nausea and vomiting in children with leukemia who are receiving chemotherapy.

  Recruiting Anhui Provincial Children's Hospital · Hefei, Anhui · NCT06756022

• Using guided imagery to reduce nausea and vomiting in children undergoing chemotherapy

  This study is testing if using guided imagery can help reduce nausea and vomiting in children aged 7 to 18 who are receiving chemotherapy.

  Recruiting Baskent University · Ankara, Ankara · NCT06120764

• Using Thalidomide to Reduce Nausea from Chemotherapy in Pancreatic Cancer

  This study is testing if thalidomide can help reduce nausea and improve the quality of life for people with pancreatic cancer who are receiving chemotherapy.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT06017284

• Using digital technology to manage chemotherapy-related nausea and vomiting in older adults

  This study is testing a digital program to help older adults manage nausea and vomiting while they go through chemotherapy to see if it improves their quality of life.

  Recruiting at 2 sites University of Central Florida · Miami, Florida and 1 other locations · NCT05838638

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.